Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care


Purpose of Review

To examine the quantifiable economic impact of inflammatory bowel disease (IBD), key cost drivers and determinants, and the impact of value-based care in IBD. Finally, we prognosticate on future directions and opportunities on healthcare economics in IBD.

Recent Findings

New value-based initiatives, technologically driven interventions, and quality improvement programs have demonstrated reductions in healthcare utilization and enhanced patient outcomes, and several have realized cost of care reductions.


IBD is a costly, chronic illness with unbalanced spending by a small proportion of individuals. Pharmaceutical costs are overtaking inpatient expenses as the primary cost driver. Value-based care initiatives including the IBD medical home, remote monitoring platforms such as myIBDcoach and Project Sonar, and learning healthcare networks exemplified by ImproveCareNow have all demonstrated successes in improving care quality, patient outcomes, and reduced healthcare spending in some populations. The future of value-based care in IBD is bright, with ample opportunities for model refinement, collaboration, and growth.

This is a preview of subscription content, log in to check access.


Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.

    Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–78. https://doi.org/10.1016/S0140-6736(17)32448-0.

  2. 2.

    Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012;26(11):811–7. https://doi.org/10.1155/2012/984575.

  3. 3.

    Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012. https://doi.org/10.1053/j.gastro.2011.10.001.

  4. 4.

    Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–7. https://doi.org/10.1038/nrgastro.2015.150.

  5. 5.

    Silverstein MD, Loftus J, Sandborn WJ, et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117(1):49–57. https://doi.org/10.1016/S0016-5085(99)70549-4.

  6. 6.

    Bernstein CN, Loftus EV, Ng SC, Lakatos PL, Moum B. Hospitalisations and surgery in Crohn’s disease. Gut. 2012;61(4):622–9. https://doi.org/10.1136/gutjnl-2011-301397.

  7. 7.

    Regueiro MD, McAnallen SE, Greer JB, Perkins SE, Ramalingam S, Szigethy E. The inflammatory bowel disease specialty medical home: a new model of patient-centered care. Inflamm Bowel Dis. 2016. https://doi.org/10.1097/MIB.0000000000000819.

  8. 8.

    Thorpe KE. Factors accounting for the rise in health-care spending in the United States: the role of rising disease prevalence and treatment intensity. Public Health. 2006;120(11):1002–7. https://doi.org/10.1016/j.puhe.2006.09.001.

  9. 9.

    Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135(6):1907–13. https://doi.org/10.1053/j.gastro.2008.09.012.

  10. 10.

    Bounthavong M, Li M, Watanabe JH. An evaluation of health care expenditures in Crohn’s disease using the United States medical expenditure panel survey from 2003 to 2013. Res Soc Adm Pharm. 2017;13(3):530–8. https://doi.org/10.1016/j.sapharm.2016.05.042.

  11. 11.

    Hay JH. Inflammatory bowel disease. J Clin Gastroenterol. 1992;14(4):309–17.

  12. 12.

    Kawalec P. Indirect costs of inflammatory bowel diseases: Crohn’s disease and ulcerative colitis. A systematic review. Arch Med Sci. 2016;12(2):295–302. https://doi.org/10.5114/aoms.2016.59254.

  13. 13.

    Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31(7):693–707. https://doi.org/10.1111/j.1365-2036.2010.04234.x.

  14. 14.

    Solberg IC, Vatn MH, Høie O, Stray N, Sauar J, Jahnsen J, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5(12):1430–8. https://doi.org/10.1016/j.cgh.2007.09.002.

  15. 15.

    Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN study). Scand J Gastroenterol. 2009;44(4):431–40. https://doi.org/10.1080/00365520802600961.

  16. 16.

    Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn’s disease: a payor perspective. Am J Gastroenterol. 2000;95(8):1955–60. https://doi.org/10.1016/S0002-9270(00)01053-4.

  17. 17.

    Park KT, Colletti RB, Rubin DT, Sharma BK, Thompson A, Krueger A. Health insurance paid costs and drivers of costs for patients with Crohn’s disease in the United States. Am J Gastroenterol. 2016. https://doi.org/10.1038/ajg.2015.207.

  18. 18.

    Bates DW, Saria S, Ohno-Machado L, Shah A, Escobar G. Big data in health care: using analytics to identify and manage high-risk and high-cost patients. Health Aff. 2014;33(7):1123–31. https://doi.org/10.1377/hlthaff.2014.0041.

  19. 19.

    Loly C, Belaiche J, Louis E. Predictors of severe Crohn’s disease. Scand J Gastroenterol. 2008. https://doi.org/10.1080/00365520801957149.

  20. 20.

    Limsrivilai J, Stidham RW, Govani SM, Waljee AK, Huang W, Higgins PDR. Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2017. https://doi.org/10.1016/j.cgh.2016.09.012.

  21. 21.

    Click B, Ramos Rivers C, Koutroubakis IE, et al. Demographic and clinical predictors of high healthcare use in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016. https://doi.org/10.1097/MIB.0000000000000763.

  22. 22.

    Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009. https://doi.org/10.1111/j.1365-2036.2009.04033.x.

  23. 23.

    Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease - Modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008. https://doi.org/10.1111/j.1365-2036.2008.03709.x.

  24. 24.

    Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012. https://doi.org/10.1038/ajg.2012.127.

  25. 25.

    Targownik LE, Benchimol EI, Witt J, et al. The effect of initiation of anti-TNF therapy on the subsequent direct health care costs of inflammatory bowel disease. Inflamm Bowel Dis. 2019. https://doi.org/10.1093/ibd/izz063.

  26. 26.

    Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut. 2014. https://doi.org/10.1136/gutjnl-2013-305607.

  27. 27.

    Abou Khalil M, Boutros M, Nedjar H, Morin N, Ghitulescu G, Vasilevsky CA, et al. Incidence rates and predictors of colectomy for ulcerative colitis in the era of biologics: results from a provincial database. J Gastrointest Surg. 2018;22(1):124–32. https://doi.org/10.1007/s11605-017-3530-y.

  28. 28.

    Jeuring SFG, van den Heuvel TRA, Liu LYL, Zeegers MP, Hameeteman WH, Romberg-Camps MJ, et al. Improvements in the long-term outcome of Crohn’s disease over the past two decades and the relation to changes in medical management: results from the population-based IBDSL cohort. Am J Gastroenterol. 2017;112(2):325–36. https://doi.org/10.1038/ajg.2016.524.

  29. 29.

    Lazarev M, Uliman T, Schraut WH, Kip KE, Saul M, Regueiro M. Small bowel resection rates in Crohn’s disease and the indication for surgery over time: experience from a large tertiary care center. Inflamm Bowel Dis. 2010;16(5):830–5. https://doi.org/10.1002/ibd.21118.

  30. 30.

    Wegner SE. Measuring Value in Health Care: The Times, They Are A Changin’. N C Med J. 2016;77(4):276–8. https://doi.org/10.18043/ncm.77.4.276.

  31. 31.

    Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA J Am Med Assoc. 2012. https://doi.org/10.1001/jama.2012.362.

  32. 32.

    Melmed GY, Siegel CA, Spiegel BM, et al. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013;19(3):662–8. https://doi.org/10.1097/mib.0b013e31828278a2.

  33. 33.

    Donabedian A. Evaluating the quality of medical care. Reprinted 1966 article. Milbank Q. 2005;83(4):691–729. https://doi.org/10.1111/j.1468-0009.2005.00397.x.

  34. 34.

    Porter ME. What is value in health care? N Engl J Med. 2010. https://doi.org/10.1056/NEJMp1011024.

  35. 35.

    Berry SK, Melmed GY. Quality indicators in inflammatory bowel disease. Intest Res. 2018;16(1):43–7. https://doi.org/10.5217/ir.2018.16.1.43.

  36. 36.

    Physician Quality Reporting System (PQRS) measures list. 2013.

  37. 37.

    Kim AH, Roberts C, Feagan BG, et al. Developing a standard set of patient-centred outcomes for inflammatory bowel disease-an international, cross-disciplinary consensus. J Crohn's Colitis. 2018. https://doi.org/10.1093/ecco-jcc/jjx161.

  38. 38.

    •• Regueiro M, Click B, Anderson A, et al. Reduced unplanned care and disease activity and increased quality of life after patient enrollment in an inflammatory bowel disease medical home. Clin Gastroenterol Hepatol. 2018. https://doi.org/10.1016/j.cgh.2018.04.007 This study assesses the impact of a novel value-based care initiative - the IBD Medical Home - and demonstrates reductions in healthcare utilization along with improvement in patient outcomes and quality of life.

  39. 39.

    Regueiro M, Click B, Holder D, Shrank W, McAnallen S, Szigethy E. Constructing an inflammatory bowel disease patient–centered medical home. Clin Gastroenterol Hepatol. 2017. https://doi.org/10.1016/j.cgh.2017.05.026.

  40. 40.

    Regueiro MD, McAnallen SE, Greer JB, Perkins SE, Ramalingam S, Szigethy E. The inflammatory bowel disease specialty medical home. Inflamm Bowel Dis. 2016. https://doi.org/10.1097/mib.0000000000000819.

  41. 41.

    L. K, J.V. B, M. S, C. B, R. T, P. L-B. Project Sonar: Reduction in cost of care in an attributed cohort of patients with crohn’s disease. Gastroenterology. 2016.

  42. 42.

    •• de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390(10098):959–68. https://doi.org/10.1016/S0140-6736(17)31327-2 This study is a prospective, multicenter, randomized trial using a unique remote monitoring platform to manage a population of inflammatory bowel disease patients.

  43. 43.

    Colombara F, Martinato M, Girardin G, Gregori D. Higher levels of knowledge reduce health care costs in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015. https://doi.org/10.1097/MIB.0000000000000304.

  44. 44.

    Cross RK, Arora M, Finkelstein J. Acceptance of telemanagement is high in patients with inflammatory bowel disease. J Clin Gastroenterol. 2006. https://doi.org/10.1097/00004836-200603000-00006.

  45. 45.

    Bilgrami Z, Abutaleb A, Chudy-Onwugaje K, Langenberg P, Regueiro M, Schwartz DA, et al. Effect of telemedicine for inflammatory bowel disease on patient activation and self-efficacy. Dig Dis Sci. 2019;65:96–103. https://doi.org/10.1007/s10620-018-5433-5.

  46. 46.

    •• Cross RK, Langenberg P, Regueiro M, et al. A randomized controlled trial of telemedicine for patients with inflammatory bowel disease (TELE-IBD). Am J Gastroenterol. 2018. https://doi.org/10.1038/s41395-018-0272-8 This study is a prospective, randomized trial evaluating the efficacy of telemedicine for the management of inflammatory bowel disease.

  47. 47.

    Quinn CC, Chard S, Roth EG, Eckert JK, Russman KM, Cross RK. The telemedicine for patients with inflammatory bowel disease (TELE-IBD) clinical trial: qualitative assessment of participants’ perceptions. J Med Internet Res. 2019;21(6):e14165. https://doi.org/10.2196/14165.

  48. 48.

    Pedersen N, Elkjaer M, Duricova D, et al. EHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease. Aliment Pharmacol Ther. 2012. https://doi.org/10.1111/apt.12043.

  49. 49.

    Helsel BC, Williams JE, Lawson K, Liang J, Markowitz J. Telemedicine and mobile health technology are effective in the management of digestive diseases: a systematic review. Dig Dis Sci. 2018;63:1392–408. https://doi.org/10.1007/s10620-018-5054-z.

  50. 50.

    Crandall W, Kappelman MD, Colletti RB, et al. ImproveCareNow: the development of a pediatric inflammatory bowel disease improvement network. Inflamm Bowel Dis. 2011. https://doi.org/10.1002/ibd.21394.

  51. 51.

    Calvet X, Panés J, Alfaro N, Hinojosa J, Sicilia B, Gallego M, et al. Delphi consensus statement: quality indicators for inflammatory bowel disease comprehensive care units. J Crohns Colitis. 2014;8(3):240–51. https://doi.org/10.1016/j.crohns.2013.10.010.

  52. 52.

    ICHOM | Inflammatory bowel disease standard set | Measuring Outcomes. https://www.ichom.org/portfolio/inflammatory-bowel-disease/. Accessed 4 Nov 2019.

  53. 53.

    Nguyen GC, Devlin SM, Afif W, Bressler B, Gruchy SE, Kaplan GG, et al. Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol. 2014;28(5):275–85. https://doi.org/10.1155/2014/941245.

Download references

Author information

Correspondence to Benjamin H. Click.

Ethics declarations

Conflict of Interest

Benjamin Click reports personal fees from Takeda Pharmaceuticals, outside the submitted work.

Jonathan Beard and Diana Franco declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


BC serves on speakers’ bureau for Takeda.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Inflammatory Bowel Disease

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Beard, J.A., Franco, D.L. & Click, B.H. The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care. Curr Gastroenterol Rep 22, 6 (2020). https://doi.org/10.1007/s11894-020-0744-z

Download citation


  • Value-based care
  • Quality
  • Cost
  • Specialty medical home
  • Patient-centered medical home
  • Inflammatory bowel disease
  • Donabedian
  • Biologics